Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gsk2816126. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 known ✓ | Q15910 | 17/20 | 1.00 |
| ▸ | EZH1 | Q92800 | 6/20 | 1.00 |
| ▸ | EED | O75530 | 3/20 | 1.00 |
| ▸ | SUZ12 | Q15022 | 3/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.80 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.75 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.62 |
| ▸ | RBBP7 | Q16576 | 1/20 | 0.62 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gsk2816126 SCHEMBL12180401 | 1.00 | EZH2 (1.00) | EZH2EZH1EEDSUZ12HDAC1 | |
| Gsk2816126 SCHEMBL2593705 | 1.00 | EZH2 (1.00) | EZH2EZH1EEDSUZ12HDAC1 | |
| Gsk2816126 SCHEMBL2595737 | 1.00 | EZH2 (1.00) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL14933215 | 0.94 | EZH2 (0.90) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL19033201 | 0.94 | EZH2 (0.88) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL29308159 | 0.94 | EZH2 (0.88) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL18768926 | 0.94 | EZH2 (0.88) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL2594075 | 0.94 | EZH2 (1.00) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL2594727 | 0.93 | EZH2 (0.88) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL14726845 | 0.93 | EZH2 (0.88) | EZH2EZH1EEDSUZ12HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1087 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629364-B2 | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and platinum-based antineoplastic drugs | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2026-05-19 | — | — | US | claimed |
| WO-2026102034-A1 | COMPOSITIONS AND METHODS FOR GENETIC AND EPIGENETIC MODULATION | JUNIPERO THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| WO-2026099526-A1 | COMBINATION OF INHIBITORS OF IL-1BETA, CCR5 OR CXCR2 CYTOKINE RECEPTORS FOR USE IN THE TREATMENT OF METASTASIS | FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA (ES) | 2026-05-15 | — | — | WO | claimed |
| EP-4720133-A1 | GD2-SPECIFIC CHIMERIC ANTIGEN RECEPTOR EFFECTOR CELLS FOR USE IN THE TREATMENT OF SOLID TUMORS, POSSIBLY IN COMBINATION WITH ENHANCER OF ZESTE HOMOLOG 2 (EZH2) INHIBITORS | Ospedale Pediatrico Bambino Gesù (IT) | 2026-04-08 | — | — | EP | claimed |
| EP-4048260-B1 | COMBINATION OF SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING A HEMATOLOGICAL MALIGNANCY | CELGENE CORP (US) | 2026-03-11 | — | — | EP | claimed |
| US-12571049-B2 | Therapeutic treatment of select diffuse large B cell lymphomas exhibiting distinct pathogenic mechanisms and outcomes | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-03-10 | — | — | US | claimed |
| US-12564559-B2 | Combinations of LSD1 inhibitors for use in the treatment of solid tumors | ORYZON GENOMICS, S.A. (ES) | 2026-03-03 | — | — | US | claimed |
| EP-4684836-A2 | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | Oryzon Genomics, S.A. (ES) | 2026-01-28 | — | — | EP | claimed |
| EP-4684803-A1 | ANTIBODY CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF RBM39 AND THERAPEUTIC USES THEREOF | CeMM - Forschungszentrum für Molekulare Medizin GmbH (AT) | 2026-01-28 | — | — | EP | claimed |
| US-12529091-B2 | ATAC-array for prediction of disease-free survival in pancreatic cancer | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2026-01-20 | — | — | US | claimed |
| US-11298328-B2 | Sensorineural hair cell differentiation | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2022-04-12 | — | — | US | claimed |
| CN-114177299-A | Antitumor pharmaceutical composition containing EZH2 inhibitor and SCD1 inhibitor and application thereof | 北京大学第三医院（北京大学第三临床医学院） | 2022-03-15 | — | — | CN | claimed |
| CN-114159441-A | Application of GSK126 in preparation of medicine for treating oxaliplatin-resistant colon cancer | 中南大学 | 2022-03-11 | — | — | CN | claimed |
| WO-2022042527-A1 | SMALL-MOLECULE DRUG FOR TREATING DISEASES RELATED TO INNER EAR AND INTESTINAL EPITHELIAL TISSUE INJURIES | 北京大学 | 2022-03-03 | — | — | WO | claimed |
| CN-114085803-A | Establishment of organoid culture systems with regenerative properties | 北京大学 | 2022-02-25 | — | — | CN | claimed |
| CN-111269878-B | Special culture medium for converting human pluripotent stem cells into expanded pluripotent stem cells and application of special culture medium | 深圳市北科生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| CN-114028397-A | Application of GSK126 serving as EZH2 inhibitor in preparation of medicine for preventing and/or treating cerebral arterial thrombosis | 徐州医科大学 | 2022-02-11 | — | — | CN | claimed |
| WO-2022026932-A2 | DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-02-03 | — | — | WO | claimed |
| WO-2022026933-A2 | IN VITRO DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-02-03 | — | — | WO | claimed |
| US-20220023293-A1 | EZH2- FGFR INHIBITION IN CANCER | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis (NL) | 2022-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12571049-B2 | Therapeutic treatment of select diffuse large B cell lymphomas exhibiting distinct pathogenic mechanisms and outcomes | BCL6, BCL3, BCL6B | EZH2 25/4885EZH1 124/4885EED 958/4885 |
| US-12564559-B2 | Combinations of LSD1 inhibitors for use in the treatment of solid tumors | EZH2, BRDT, DOT1L | EZH2 1/4885EZH1 11/4885EED 92/4885 |
| US-12629364-B2 | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and platinum-based antineoplastic drugs | EZH2, CARM1, PRMT6 | EZH2 1/4885EZH1 10/4885EED 16/4885 |
| US-12529091-B2 | ATAC-array for prediction of disease-free survival in pancreatic cancer | ABCC1, EPCAM, ABCF2 | EZH2 582/4885EZH1 147/4885EED 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.